About Us
Afecta Pharmaceuticals is an early clinical stage biotech company focused on more efficiently discovering and developing new precision medicines to treat chronic disorders and cancers that are especially prevalent in women and children.
Our Approach
We are developing new precision medicines with the potential to transform treatment paradigms across several therapeutic areas. Our approach leverages proprietary technologies to create risk-mitigated candidate drugs, formulate them into improved medicines with enhanced benefit-risk profiles and move them into clinical use more rapidly and at lower cost.
Early and Late-Stage Asset Development
Afecta's market segmented business model and diverse pipeline of early and late-stage drug assets create value from both the potential of our technology platforms as well as our clinical products. Our business model also enables a modular approach to the potential commercialization of new therapies as we advance each asset through development.
History
Afecta was founded by physician-scientists at the University of Southern California, City of Hope/Beckman Research Institute, University of California Irvine, and the California Institute of Technology, with the mission of developing novel, innovative pharmaceutical products through the application of molecular genetic technologies to classify diseases, sub-type patient groups, identify key disease pathways, and identify new drugs to more safely and effectively treat these disorders. The first drugs discovered by Afecta were licensed to Supernus (NASDAQ: SUPN). In the years since, we have been fortunate to have attracted pharmaceutical industry veterans who have demonstrated a successful track record across the full spectrum of drug development and commercialization.
